Screener
LB Pharmaceuticals Inc LBRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $320,676 | $250,173 |
| Marketable securities | 44,960 | 45,040 |
| Prepaid expenses and other current assets | 23,438 | 13,219 |
| Total current assets | 389,074 | 308,432 |
| Operating lease right-of-use assets, net | 2,101 | 2,151 |
| Property and equipment, net | 1,531 | 1,581 |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's cash & equivalents?
- LB Pharmaceuticals Inc (LBRX) reported cash & equivalents of $320.68M in Q1 2026.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about LB Pharmaceuticals Inc's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude